An observational study in Chikungunya Fever, sponsored by Centre Hospitalier Universitaire de la Réunion. Completed at 1 site in Réunion. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-30.
Sponsored by Centre Hospitalier Universitaire de la Réunion · Observational
Chikungunya virus (CHIKV) infection has become a threat to public health worldwide. Reunion Island, due to the 2005-2006 epidemic, has acquired unique expertise and remains at the forefront of global research on this disease. The idea of genetic determinism of the clinical expression of infectious diseases has been supported by many epidemiological arguments over the past fifty years. The identification of genetic variants, associated with a disease, often allows a better understanding of the molecular mechanisms involved with consequent significant benefits such as the development of specific biomarkers for new preventive (vaccination) and / or therapeutic (drug design) approaches. In the absence of well-documented hypotheses about the genes potentially involved in the occurrence or evolution of a disease, genome-wide association studies (GWAS), whole genome, of nucleotide polymorphisms (SNPs) and the principle of linkage disequilibrium, under the commonly accepted hypothesis that the expression of a common disease is based on a small number of alleles commonly found in the population (frequency of minor allele greater than 1-5%), have become a method of choice, free of hypothesis, to specify the part of heritability of a complex disease and to identify its genetic determinants. Several epidemiological arguments support a significant proportion of genetic determinism in the explanation of the evolutionary pattern of Chikungunya, whose proportion of chronic forms can reach 40-60% in population-based studies conducted in the two years following an epidemic:
These elements justify the interest of a GWAS in the Chikungunya to identify new avenues and mechanistic hypotheses likely to explain the chronic arthralgia characteristic of the disease.
84 studies on the registry are indexed under Chikungunya Fever; 18 are open to participants now.
This study's enrollment of 600 is close to the median of 570 across 25 observational studies indexed under Chikungunya Fever.
Browse Chikungunya Fever studies →Centre Hospitalier Universitaire de la Réunion is the lead sponsor of 137 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subject with a serological status known for Chikungunya virus for the period between March 1st, 2005 and December 31st, 2006 (epidemic period in reunion Island).
Exclusion Criteria:
* Clinical examination; * Quality of life survey; * Saliva collection for genetical analysis
Other: Quality of life survey · Genetic: Saliva collection
* Clinical examination; * Quality of life survey; * Saliva and blood collection for genetical analysis
Other: Quality of life survey · Genetic: Saliva collection · Genetic: Blood collection
Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
Collection of 20 ml of saliva with a kit of saliva collection
Collection of 20 ml of blood with kit of blood collection
identify by a genome-wide association study the genetic factors associated with the evolutionary profile of Chikungunya
to determine if certain genetic profiles may be predictive of progression to asymptomatic or acute disease, or to the chronic character of the manifestations of the disease
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de la Réunion